Innovations in Cardiovascular Disease Management: Latest Surgical Procedures, Drugs and Medical Devices.LYON, France -- Reportlinker.com announces that a new market research report related to the worldwide pharmaceutical industry is now available to its catalogue. Innovations in Cardiovascular Disease Management: Latest surgical procedures, drugs and medical devices http://www.reportlinker.com/p058864/Cardiovascular-Disease- Management.html (Due to its length, this URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) Despite significant advances in prevention and treatment, cardiovascular disease remains the leading cause of death in economically advanced countries. The developing world has also begun to experience a disconcerting dis·con·cert tr.v. dis·con·cert·ed, dis·con·cert·ing, dis·con·certs 1. To upset the self-possession of; ruffle. See Synonyms at embarrass. 2. growth in prevalence, where the insurgence in·sur·gence n. The action or an instance of rebellion; an insurrection. insurgency, insurgence 1. the state or condition of being in revolt or insurrection. 2. an uprising. of CVD CVD Cardiovascular disease, see there has exacerbated the risk factors associated with indigenous communicable diseases. Keeping pace with epidemiological change in both the developed and developing world constitutes the overriding challenge for industrial players, and involves successfully integrating into localised healthcare systems and reimbursement structures, in addition to remaining aligned with product demand. In the medical device, pharmaceutical and biotechnology industries, this challenge is being met with a focus on products that reduce adverse effects, improve patient outcomes and extend the range of formulations for existing indications. 'Innovations in Cardiovascular Disease Management' is a new report that will examine the major developments shaping the future of the cardiovascular industry. This report will analyse the future potential of new and emerging products from the medical device, pharmaceutical and biotechnology sectors, and measure their likely impact upon the existing market. The extent to which these products can stimulate the growth and development of the future market will also be assessed. Use this report to evaluate the potential of new and emerging products in the treatment of cardiovascular diseases, assess the strength of competitor pipelines and identify future market opportunities... Table of content Executive Summary The Management of Cardiovascular Disease Cardiovascular and Interventional Procedures Emerging Coronary Stents and Stent Systems Innovations in Minimally Invasive Cardiac Surgery minimally invasive cardiac surgery Interventional cardiology Any of a number of techniques–MIDCAB, off-pump coronary-artery bypass, minimally invasive valve surgery, port-access coronary surgery, and port-access valve surgery–increasingly being used to Cardiovascular Drugs in Early Stage Development New and Emerging Cardiovascular Drugs Chapter 1 The Management of Cardiovascular Disease Summary Introduction The Global Burden of Cardiovascular Disease CVD remains the leading cause of death in the United States CVD Rates in Central and Eastern Europe The term "Central and Eastern Europe" came into wide spread use, replacing "Eastern bloc", to describe former Communist countries in Europe, after the collapse of the Iron Curtain in 1989/90. Noncommunicable Diseases in the Developing World Background to the Major Cardiovascular Conditions Coronary Artery Disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. (CAD) Atherosclerosis Angina Pectoris Acute Myocardial Infarction acute myocardial infarction (  ·kyōōtˑ mī·ō·karˑ·dē· (MI)
Heart Valve Disorders Aortic heart valve Mitral Valve Disease Pulmonary Valve Disease Tricuspid Valve Disease High Blood Pressure: Hypertension Heart Rhythm Disorders (Heart Arrhythmia) Peripheral Vascular Disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. Peripheral Artery Disease (PAD) Peripheral Venous Disorders (PVD PVD abbr. peripheral vascular disease PVD Peripheral vascular disease, see there ) Stroke or Cerebrovascular Accidents (CVA CVA abbr. cerebrovascular accident CVA, n See accident, cerebrovascular. CVA cerebrovascular accident. CVA Cerebrovascular accident, see there ) Ischaemic Stroke Haemorrhagic stroke Chapter 2 Latest Developments in Cardiovascular and PCI (1) (Payment Card Industry) See PCI DSS. (2) (Peripheral Component Interconnect) The most widely used I/O bus (peripheral bus). Procedures Summary Introduction to Percutaneous Coronary Interventions Indications for PCI PCI Procedural Volumes PCI Used Primarily to Treat Unstable Angina and acute ST-elevation MI Inter-country Variance in PCI Procedural Rates China and India: Huge growth potential and market development Latest Developments in PCI Procedures Embolic Protection Devices Current Products Development Stage Products and Current Status Future Technologies and Trends Coronary Atherectomy Rotational Coronary Atherectomy (Rotoblation) Directional Coronary Atherectomy directional coronary atherectomy Cardiology A method of coronary revascularization, in which targeted atherosclerotic plaques are excised and removed. See Balloon coronary angioplasty, Coronary revascularization, Stent placement. (DCA (1) (Document Content Architecture) IBM file formats for text documents. DCA/RFT (Revisable-Form Text) is the primary format and can be edited. DCA/FFT (Final-Form Text) has been formatted for a particular output device and cannot be changed. ) Orbital Atherectomy Ablative ablative (ăb`lətĭv') [Lat.,=carrying off], in Latin grammar, the case used in a number of circumstances, particularly with certain prepositions and in locating place or time. The term is also used in the grammar of some languages (e.g. laser-assisted angioplasty Chapter 3 Emerging Coronary Stents and Stent Systems Summary Emerging Coronary Stents and Stent Systems Key Events Introduction of Drug-Eluting Stents (DES) Development of Drug-Eluting Stents Sirolimus (Rapamycin) Paclitaxel Tacrolimus Everolimus (RAD-001) Zotarolimus (also called ABT-578) DES - Recent News, Product Developments and Clinical Trial Updates Market Developments and Forecasts for Drug-Eluting Stents Emergence of Bioabsorbable Stents Biomaterials and Bioabsorbable Polymers Further Coronary Stent Developments and Technological Trends Novel Coating Technologies Gene Therapy technologies and its Potential Use to Prevent Restenosis Coronary Stents and Endothelial Progenitor Cells (EPCs) Nanotechnologies and Drug-Eluting Coronary Stents Development of Novel Estradiol Containing Drug-Eluting Stents Stem-Cell Derived Endovascular Cells Chapter 4 Innovations in Minimally Invasive Cardiac Surgery (MICS) Summary Introduction Minimally Invasive Direct Coronary Artery Bypass Coronary artery bypass Surgical procedure to reroute blood around a blocked coronary artery. Mentioned in: Heart Failure coronary artery bypass, n (MID-CAB) Indications for MIDCAB MIDCAB Minimally invasive direct coronary artery bypass Cardiology Minimally invasive heart surgery in which coronary bypass–usually with a single graft is performed on a blood-filled beating heart without a heart-lung machine via a small incision in the Off-Pump Coronary Artery Bypass (OP-CAB) Indications for OP-CAB Minimally Invasive Port Access Indications for Minimally Invasive Port Access Robotic Assisted Coronary Artery Bypass (RA-CAB) Current and Emerging Technologies Robotics in Minimally Invasive Cardiac Surgery Robotic Systems Computer Aided Cardiac Surgery Virtual Reality in Cardiac Surgery Laser Heart Surgery or transmyocardial Laser revascularization (TMLR TMLR Transmyocardial Laser Revascularization ) The CO2 Heart Laser System The holmium holmium (hōl`mēəm) [Lat.,=Stockholm], metallic chemical element; symbol Ho; at. no. 67; at. wt. 164.9304; m.p. about 1,474°C;; b.p. about 2,425°C;; sp. gr. 8.78 at 25°C;; valence +3. :YAG (yttrium aluminium garnet
The excimer laser Chapter 5 Cardiovascular Drugs in Early Stage Development Summary Introduction Early Developments in Key Cardiovascular Disease Classes Angina Arrhythmiasis Atherosclerosis Atrial Fibrillation Congestive Heart Failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. Hypercholesterolemia Hypertension Myocardial Infarction Thrombosis Chapter 6 New and Emerging Cardiovascular Drugs Summary Introduction Anti-Hypertensives Tekturna (Aliskiren) Development of a New Class of Renin renin /re·nin/ (re´nin) a proteolytic enzyme synthesized, stored, and secreted by the juxtaglomerular cells of the kidney; it plays a role in regulation of blood pressure by catalyzing the conversion of angiotensinogen to angiotensin I. Inhibitors Exforge (valsartan plus amlodipine) CHF-1521 Cleviprex(TM) (Clevidipine) Antihypertensives: Current Pipeline and Late Stage Development Cardoxal (MC-4232) (MC-1 cardioprotectant plus lisinopril) Darusentan Ambrisentan Nebivolol Zanipress[R] / Zanitek[R] Thelin[TM] (Sitaxsentan) TBC3711 Anti-Dyslipidemics Pfizer discontinues torcetrapib development R1658 Simcor (Niaspan[R] (extended-release niacin) and simvastatin simvastatin /sim·va·stat·in/ (sim´vah-stat?in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used in the treatment of hypercholesterolemia and other forms of dyslipidemia and to lower the risks associated (generic Zocor[R])) CRESTOR[R] (rosuvastatin) and CRESTOR/ABT-335 combination Synordia Lapaquistat (TAK-475) SLx-4090 AEGR-733 Compound Number 256073 and 501516 LBM642 Dyslipidaemia: Current Pipeline and Late Stage Development Anti-Thrombotics Rivaroxaban (BAY59-7939) Rendix (dabigatran etexilate, BIBR-1048) Idraparinux Apixaban SSR-126517 Exanta/ximelagatran Anti-Thrombotics: Current Pipeline and Late Stage Development Anti-Arrhythmics Stedicor (Azimilide) Multaq (Dronedarone) Vernakalalant (RSD RSD Reflex sympathetic dystrophy, see there 1235) Tecadenoson CVT510 Pulzium IV (Tedisamil) Anti-Arrhythmics: Current Pipeline and Late Stage Development Chapter 7 Appendix Methodology Statement Primary Data and Information Gathering Secondary Data and Information Gathering Market Share Analysis and Market Forecast Predictions Glossary Index List of Figures Figure 1.1: Breakdown of Deaths from Cardiovascular Diseases, USA 2002 Figure 1.2: Leading causes of death in developing countries, 2002 Figure 2.3: Use of Percutaneous Coronary Intervention in Europe, 2005 Figure 3.4: Estimated number of Stent Procedures (BMS & DES) % Total Number of PTCA PTCA abbr. percutaneous transluminal coronary angioplasty PTCA Percutaneous transluminal coronary angioplasty, see there Procedures Figure 3.5: Actual and projected revenues from Coronary Stents, Worldwide sales- 2006 Figure 3.6: Market Share Analysis, DES v BMS World, 2006 List of Tables Table 1.1: Age- and gender-specific incidence of recognised MI Table 1.2: Age- and gender-specific incidence of unrecognised MI Table 2.3: Estimated volume of cardiovascular procedures by region (US 2002) Table 2.4: PCI procedure rates in Selected Countries, 2005 Table 5.5: Selected Early Stage Anti Anginal Drug Developments Table 5.6: Selected Early Stage Anti Arrhythmiasis Drug Developments Table 5.7: Selected Early Stage Atherosclerosis Drug Developments Table 5.8: Selected Early Stage Atrial Fibrillation Drug Developments Table 5.9: Selected Early Stage Congestive Heart Failure Drug Developments Table 5.10: Selected Early Stage Hypercholesterolemia Drug Developments Table 5.11: Selected Early Stage Hypertension Drug Developments Table 5.12: Selected Early Stage Myocardial Infarction Drug Developments Table 5.13: Selected Early Stage Thrombosis Drug Developments Table 6.14: Characteristics of Major Classes of Lipoproteins Table 6.15: AstraZeneca's Current Anti-Dyslipidaemia Pipeline Table 6.16: Classification of Anti-Arrhythmics More market research reports? Go to http://www.reportlinker.com http://www.reportlinker.com/ci0228/Cardiovascular-diseases-market -research.html http://www.reportlinker.com/ci0133/Pharmaceutical-industry-market -research.html http://agribusinessmarket.wordpress.com (Due to their length, these URLs may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion